TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16905398
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy with a group of relatives
Study: 10788287
Drug: Social support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social support intervention administered by nurse and peer advisors
Study: 8706290
Drug: 3% saline
Normalized name: dextrose 2.5%-0.3% saline (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% saline infusion followed by oral water load (10 ml/kg over 3 minutes)
Study: 1829098
Drug: Steroid suppressive
Normalized name: Buckley's Cough Suppressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid suppressive agents (aminoglutethimide, ketoconazole, metyrapone) for 2 months
Study: 1829098
Drug: Not applicable
Normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not applicable (discontinuation of other psychotropic drugs)
Study: 7020903
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with melphalan, 5-fluorouracil, and methotrexate
Study: 7020903
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy with melphalan followed by 5-fluorouracil and then methotrexate
Study: 31134632
Drug: Pegbelfermin (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegbelfermin (daily and weekly administration)
Study: 29166972
Drug: Neonatal vitamin
Normalized name: NEONATAL VITAMIN Tablet
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neonatal vitamin A supplementation (any dose)
Study: 22303701
Drug: N-acetyl-cysteine (NAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl-cysteine (NAC) administered orally before noise exposure
Study: 22303701
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally before noise exposure
Study: 19640356
Drug: Desoxypeganine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desoxypeganine 50 mg (b.i.d. for 3 days)
Study: 19640356
Drug: Desoxypeganine 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desoxypeganine 100 mg (b.i.d. for 3 days)
Study: 17676355
Drug: Control (pre-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (pre-treatment results)
Study: 11344201
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (200 mg/week, im)
Study: 8013019
Drug: Low-dose dobutamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dobutamine echocardiography (5-10 mcg/kg/min over 5 min)
Study: 8013019
Drug: High-dose dobutamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dobutamine echocardiography (20-40 mcg/kg/min over 3 min)
Study: 8013019
Drug: Dipyridamole echocardiography
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dipyridamole echocardiography (0.56 mg/kg over 4 min + 0.28 mg/kg over 2 min)
Study: 2583149
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of caffeine per kg of body-weight in 200 ml of orange juice (CA)
Study: 2583149
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml of orange juice (C)
Study: 133601
Drug: High initial
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High initial dosage of 2,500 mg aurothioglucose in 21 weeks, followed by maintenance dosage
Study: 133601
Drug: Low dosage
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dosage of 1,000 mg gold in 21 weeks, followed by maintenance dosage
Study: 133601
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections after high dosage
Study: 133601
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections after low dosage
Study: 29065052
Drug: Caffeine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (80 mg) and Taurine (1 g)
Study: 29065052
Drug: Placebo (maltodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrin ∼1 g)
Study: 31634648
Drug: ED (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: ED (75 mg/m2 of epirubicin and 75 mg/m2 of docetaxel)
Study: 31634648
Drug: FEC (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC (500 mg/m2 of fluorouracil, 100 mg/m2 of epirubicin and 500 mg/m2 of cyclophosphamide)
Study: 19343970
Drug: Levodopa/carbidopa (0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/carbidopa (0.50 mg + 1.25 mg per kg body weight three times daily after meals)
Study: 15450833
Drug: Rofecoxib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (50 mg preoperatively)
Study: 11504983
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of PCP prophylaxis
Study: 808089
Drug: Pediatric preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric preparations of penicillin V (1 mill I.U.)
Study: 808089
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (effervescent tablets, substance for drops and granulate)
Study: 30295912
Drug: Iyengar Yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iyengar Yoga (twice-weekly for 8 weeks)
Study: 15592925
Drug: Felodipine ER
Normalized name: Felodipine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine ER tablet (10 mg) with menthol (100 mg initially, followed by 50 mg, 25 mg, and 25 mg at specified intervals)
Study: 15592925
Drug: Felodipine ER
Normalized name: Felodipine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine ER tablet (10 mg) with placebo
Study: 7616402
Drug: Intranasal cocaethylene
Normalized name: Nonylphenol octa(oxyethylene) ethanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal cocaethylene administration
Study: 1088916
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of methyldopa and hydrochlorothiazide
Study: 31911261
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose prednisone (0.5 mg/kg/day for 6 months, max 30 mg daily) and methotrexate (15-20 mg once weekly for 6 months)
Study: 31911261
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose prednisone (20 mg daily for 1 month, then 10 mg daily for 1 month, then 5 mg daily for one month then stop)
Study: 16441739
Drug: beta-TCP+0.3 mg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-TCP+0.3 mg/ml of rhPDGF-BB
Study: 16441739
Drug: beta-TCP+1.0 mg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-TCP+1.0 mg/ml of rhPDGF-BB
Study: 12900807
Drug: Pentoxifylline (PTF)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTF) 1,200 mg/d for 4 months
Study: 10871195
Drug: C-peptide kinetics
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-peptide kinetics with somatostatin infusion
Study: 10871195
Drug: C-peptide kinetics
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-peptide kinetics without somatostatin infusion
Study: 8472735
Drug: 5,000 IU
Normalized name: bleopmycin 15,000 IU Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,000 IU unfractionated heparin
Study: 8472735
Drug: 5,000 IU
Normalized name: bleopmycin 15,000 IU Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,000 IU unfractionated heparin + 0.5 mg dihydroergotamine mesylate twice daily
Study: 26914104
Drug: Acupuncture-like transcutaneous
Normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) administered over 12 weeks (24 sessions)
Study: 26914104
Drug: Oral pilocarpine
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pilocarpine (PC) 5 mg three times daily over 12 weeks
Study: 15897673
Drug: low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: low dose (S)-ketamine
Study: 15897673
Drug: high dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: high dose (S)-ketamine
Study: 10575269
Drug: Isoniazid (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid (300 mg o.d. for 3 days)
Study: 1585760
Drug: Short-contact therapy
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-contact therapy with 1% Micanol, average application time 13 minutes, increased to 2.5% and 185 minutes after six weeks
Study: 1585760
Drug: Long-contact therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-contact therapy with 0.1% Micanol, average application time 8 hours, increased to 0.33% and 14 hours after six weeks
Study: 26908127
Drug: Lanreotide Autogel®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide Autogel® (LAN) 120 mg every 4 weeks for 96 weeks
Study: 25728101
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (triamcinolone acetonide 0.1% ointment in orabase)
Study: 18006208
Drug: L-theanine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-theanine (250 mg)
Study: 18006208
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of L-theanine and caffeine
Study: 11978277
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist + daily norethindrone acetate 5 mg
Study: 11978277
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist + daily norethindrone acetate 5 mg and conjugated equine estrogens 0.625 mg
Study: 11978277
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist + daily norethindrone acetate 5 mg and conjugated equine estrogens 1.25 mg
Study: 11978277
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist + daily placebo
Study: 9348142
Drug: Bulkforming agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bulkforming agent (Volcolon: psyllium fibres)
Study: 9348142
Drug: Auranofin 6
Normalized name: Auranofin
DrugBank: Auranofin (DB00995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Auranofin 6 mgr daily
Study: 2878461
Drug: lormetazepam (0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: lormetazepam (0.06 mg/kg) with Ro 15‐1788 (0.1 mg/kg)
Study: 2878461
Drug: flunitrazepam (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: flunitrazepam (0.03 mg/kg) with Ro 15‐1788 (0.1 mg/kg)
Study: 2878461
Drug: placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo with Ro 15‐1788 (0.1 mg/kg)
Study: 2878461
Drug: Ro 15‐1788
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 15‐1788 (0.1 mg/kg) 24 h after BZ treatment
Study: 2878461
Drug: Behavioural responses
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioural responses under BZ treatment
Study: 10477323
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg carbamazepine immediate release tablets in SLS (1% sodium lauryl sulfate in water)
Study: 10477323
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg carbamazepine immediate release tablets in HC (0.1 mol/l Hydrochloric acid in water)
Study: 1850682
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion (30 ng min‐1 kg‐1)
Study: 25758472
Drug: Atacicept (150mg)
Normalized name: Atacicept
DrugBank: Atacicept (DB06399)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atacicept (150mg) administered twice weekly for 4 weeks, then once weekly for 32 weeks
Study: 21829595
Drug: Maintenance dose
Normalized name: Firmagon 80mg Powder for Injection Maintenance Dose Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance dose pegylated-IFNα for an additional 3.5 years
Study: 21829595
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional therapy group
Study: 19735787
Drug: Concurrent music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent music during gait tasks in PD patients
Study: 19735787
Drug: Concurrent music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent music during gait tasks in control subjects
Study: 19735787
Drug: Dual-task with
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-task with concurrent music in PD patients
Study: 19735787
Drug: Dual-task with
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-task with concurrent music in control subjects
Study: 9713038
Drug: Selenium enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium enriched yeast (4.8 mg containing 5 micrograms selenium daily)
Study: 7985832
Drug: Heparin flushing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin flushing three times/day by hospital IV team (Group A)
Study: 7985832
Drug: Heparin 1
Normalized name: heparin 10 units/mL injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 1 mL of 2500 units in each lumen after dialysis three times/week by dialysis nurses (Group B)
Study: 2525101
Drug: Inhaled budesonide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide, 800 micrograms twice daily via a Nebuhaler for 16 weeks
Study: 21242741
Drug: Gabapentin enacarbil
Normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin enacarbil 1200 mg administered once daily at 5 pm; dose adjustments to 600 or 1800 mg were permitted based on investigator judgment.
Study: 10920309
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg danazol 3 times daily for 6 months
Study: 10920309
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg leuprolide depot every 28 days for 6 months
Study: 10920309
Drug: Post-treatment (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-treatment (3 months after treatment)
Study: 8604441
Drug: Other Drugs
Normalized name: Other drugs for bile therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other Drugs
Study: 1575287
Drug: Praziquantel (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (20 mg/kg or 40 mg/kg body weight)
Study: 3907790
Drug: Ketamine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (1 mg . kg‐1)
Study: 3907790
Drug: Thiopentone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (4 mg . kg‐1)
Study: 30213882
Drug: Pramlintide coadministered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramlintide coadministered with regular human insulin (fixed ratio 9 μg/unit)
Study: 30213882
Drug: Placebo coadministered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo coadministered with regular human insulin
Study: 20042769
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA (2 g/d)
Study: 14564683
Drug: l-thyroxine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-thyroxine therapy (1.8 mug/kg daily)
Study: 10850524
Drug: gatifloxacin 400
Normalized name: gatifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: gatifloxacin 400 mg/day orally
Study: 10850524
Drug: ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ciprofloxacin 500 mg twice/day orally
Study: 8792382
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (FPANS) 100 micrograms once daily (od)
Study: 8792382
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (FPANS) 100 micrograms twice daily (bd)
Study: 8792382
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (FPANS) 200 micrograms od
Study: 1636712
Drug: Erythromycin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (6 mg/kg)
Study: 6533789
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (Vitamin C) 1 gram administered randomly to healthy young people for two months
Study: 6533789
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (Vitamin C) 1 gram administered to healthy older people for six to twelve months
Study: 6533789
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (Vitamin C) 1 gram per day administered throughout the year
Study: 21860562
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K + vitamin D + calcium supplement (15 mg of vitamin K2 three times daily, 400 IU of vitamin D once a day, and 315 mg of calcium twice daily)
Study: 21860562
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K + vitamin D + calcium supplement
Study: 21860562
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (vitamin D + calcium supplement)
Study: 16352379
Drug: EMLA (local
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA (local anaesthetic cream)
Study: 14745753
Drug: Half-dose MR
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose MR angiography using diluted contrast medium injected at a rate of 1 mL/second
Study: 14745753
Drug: Half-dose MR
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose MR angiography using diluted contrast medium injected at a rate of 0.5 mL/second
Study: 14745753
Drug: Full-dose MR
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose MR angiography using original concentration injected at a rate of 1 mL/second
Study: 14745753
Drug: Full-dose MR
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose MR angiography using original concentration injected at a rate of 0.5 mL/second
Study: 11694767
Drug: Platin-based chemotherapy
Normalized name: platinic chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platin-based chemotherapy including new drugs (vinorelbine, gemcitabine, paclitaxel, docetaxel)
Study: 11694767
Drug: New drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: New drugs in combination with platin-based chemotherapy
Study: 9778204
Drug: Nortriptyline hydrochloride
Normalized name: Nortriptyline Hydrochloride
DrugBank: Nortriptyline (DB00540)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nortriptyline hydrochloride (started at 25 mg before bed, titrated to 75 mg/d or maximal tolerated dose)
Study: 30318066
Drug: Volanesorsen sodium
Normalized name: volanesorsen sodium
DrugBank: Volanesorsen (DB15067)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Volanesorsen sodium (antisense inhibitor of apolipoprotein C‐III)
Study: 21587143
Drug: Lactobacillus casei
Normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus casei Shirota (65 mL fermented milk drink containing 6.5×10^9 CFU daily)
Study: 17717533
Drug: Protein hydrolysate
Normalized name: Protein hydrolysate
DrugBank: Protein hydrolysate (DB09356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein hydrolysate (0.4 g kg(‐1) bw casein hydrolysate, PRO)
Study: 16837886
Drug: Oral E(2)
Normalized name: Aquasol E Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral E(2)
Study: 10872641
Drug: Ethanol infusion
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol infusion (100 mg/dL)
Study: 10872641
Drug: 5% dextrose
Normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose in water infusion
Study: 2834482
Drug: CY 222
Normalized name: Cys
DrugBank: Cysteine (DB00151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CY 222 at 200 U/kg and 250 U/kg (single-dose injection)
Study: 21095492
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of fluoxetine hydrochloride 20 mg
Study: 21095492
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of fluoxetine hydrochloride 20 mg
Study: 16492585
Drug: Erythromycin 400
Normalized name: ERYTHROMYCIN 400 mg in 5.2 g TOPICAL POWDER [API E.M ERYTHROMYCIN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 400 mg orally every 6 hours for 10 days
Study: 12580656
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg every 8 hours for 48 hours
Study: 3899020
Drug: Fresh frozen
Normalized name: Fresh frozen plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh frozen plasma 10 ml/kg on admission and at 24 hours of age
Study: 22836600
Drug: Single training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single training workload (3 series of 6 throws with a 3‐kg medicine ball)
Study: 22836600
Drug: Double training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double training workload (6 series of 6 throws with a 3‐kg medicine ball)
Study: 22836600
Drug: Training with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training with 3-kg medicine balls
Study: 16415410
Drug: Toremifen (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifen (30 mg daily for 3 menstrual cycles)
Study: 15322598
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy excluding ACEIs